Prognia
Drug Database
🇪🇺EU · EMARefusedATC: L03AB04

Alpheon(recombinant human interferon alfa-2a)

Hepatitis C, Chronic

Marketing Authorisation Holder: BioPartners GmbH

INN: interferon alfa-2a

Indication

Adult patients with histologically proven chronic hepatitis C who are positive for hepatitis C virus (HCV) antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.The efficacy of Interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Alpheon — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.